Convergence of parkin, PINK1 and α-synuclein on stress-induced mitochondrial morphological remodelling *

Kristi L. Norris¹,6, Rui Hao¹,6, Liang-Fu Chen², Chun-Hsiang Lai¹, Meghan Kapur¹, Peter J. Shaughnessy¹, Dennis Chou¹, Jin Yan¹ J. Paul Taylor³, Simone Engelender⁴, Anna E. West², Kah-Leong Lim⁵, Tso-Pang Yao¹,7

¹ Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA, 27710
² Department of Neurobiology, Duke University Medical Center, Durham, NC, USA, 27710
³ Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA, 38105
⁴ Department of Pharmacology, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 31096, Israel
⁵ Department of Physiology, National University of Singapore, Singapore
⁶ These authors contributed equally

*Running title: Parkin stimulates adaptive mitochondrial fusion

To whom correspondence should be addressed: Tso-Pang Yao, Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710 Tel.: (919) 6138654; Fax: (919) 668-3954; E-mail: tsopang.yao@dm.duke.edu

Keywords: Parkinson's disease; mitochondria morphology; parkin; α-synuclein

Background: Parkin is proposed to maintain mitochondrial QC through promoting mitophagy.

Results: Under moderate mitochondrial stress conditions, parkin stimulates mitochondrial fusion instead of mitophagy by catalyzing K63-linked ubiquitination and inactivating α-synuclein.

Conclusion: Parkin, PINK1 and α-synuclein form a regulatory circuit to regulate mitochondrial stress response.

Significance: This study provides a physiological context to functionally connect key PARK genes in the pathogenesis of Parkinson’s disease.

ABSTRACT

Mutations in parkin (PARK2), an ubiquitin ligase, cause early onset Parkinson's disease. Parkin was shown to bind, ubiquitinate, and target depolarized mitochondria for destruction by autophagy. This process, mitophagy, is considered crucial for maintaining mitochondrial integrity and suppressing Parkinsonism. Here, we report that under moderate mitochondrial stress, parkin does not translocate to mitochondria to induce mitophagy; rather, it stimulates mitochondrial connectivity. Mitochondrial stress-induced fusion requires PINK1 (PARK6), mitofusins and parkin ubiquitin ligase activity. Upon exposure to mitochondrial toxins, parkin binds α-synuclein (PARK1), and in conjunction with the ubiquitin-conjugating enzyme Ubc13,
Parkin stimulates adaptive mitochondrial fusion. Importantly, α-synuclein inactivation phenocopies parkin overexpression and suppresses stress-induced mitochondria fission, whereas Ubc13 inactivation abrogates parkin-dependent mitochondrial fusion. The convergence of parkin, PINK1 and α-synuclein on mitochondrial dynamics uncovers a common function of these PARK genes in the mitochondrial stress response and provides a potential physiological basis for the prevalence of α-synuclein pathology in Parkinson's disease.

Parkinson's disease (PD) is the most common progressive neurodegenerative movement disorder. Two prominent pathological features are associated with the neurological lesions: the appearance of cytoplasmic inclusion bodies, Lewy bodies, and defective mitochondria. Lewy bodies are mainly composed of fibrillar α-synuclein (PARK1), whose mutations and duplication/triplication have been linked to familial forms of PD (1). Although Lewy bodies have been a focus of PD pathogenesis for decades, the physiological function of α-synuclein and the underlying cause for its prevalent involvement in PD remain poorly understood. On the other hand, the characterization of genes responsible for other familial forms of PD, including parkin (PARK2), PINK1 (PARK6), and DJ1 (PARK7), have yielded compelling evidence that mitochondrial dysfunction and oxidative stress are key contributing factors to parkinsonism (2-6). Indeed, brain tissues from PD patients display signs of mitochondrial defects and oxidative stress (7), while exposure to mitochondrial toxins, such as rotenone, can cause Parkinsonian-like syndrome in rodent models (8).

The characterization of mitochondrial abnormalities in Drosophila parkin and PINK1 mutants have led to the hypothesis that these two PARK genes work in conjunction to maintain a healthy mitochondrial population. A series of studies have shown that parkin, in a PINK1-dependent manner, undergoes translocation from the cytosol to chemically depolarized mitochondria (9-12). As a RING domain-containing E3 ubiquitin ligase, parkin subsequently catalyzes mitochondrial protein ubiquitination, which results in the recognition and eventual elimination of depolarized mitochondria by autophagy (13-15). As dysfunctional mitochondria are common in PD, the removal of impaired mitochondria by mitophagy has provided an effective model to explain how parkin suppresses Parkinsonism. Indeed, many PD-associated parkin mutants were found defective in mounting mitophagy (11,12,14-16). Despite the rapid acceptance of the mitophagy model, whether parkin and PINK1 maintain mitochondrial QC solely through this irreversible process remains uncertain. The mitophagy hypothesis also does not provide an effective mechanism to explain the prevalence of α-synuclein aggregation and Lewy bodies in sporadic PD. The identification of a common biological process regulated by these key PARK genes could provide a framework to more accurately understand the molecular events that lead to PD pathogenesis.

In this report, we present evidence that in response to moderate mitochondrial stress induced by mitochondrial toxins, parkin does not bind or target mitochondria for destruction; instead it promotes mitochondrial fusion. This morphological remodelling requires parkin ubiquitin E3-ligase activity as well as PINK1 (PARK6). The stress-induced mitochondrial connectivity depends on lysine 63 (K63)-linked, ubiquitination mediated by the E2-conjugating enzyme Ubc13. We identified α-synuclein (PARK1) as a regulatory target of parkin in the mitochondrial stress response. We found that mitochondrial toxin treatments stimulate parkin-α-synuclein interaction and ubiquitination, which recruits synphilin 1, a protein that promotes α-synuclein sequestration to inclusion bodies and suppresses α-synuclein toxicity. Indeed, inactivation of α-synuclein phenocopies parkin expression and suppresses mitochondrial fission induced by mitochondrial stresses. The convergence of parkin, PINK1 and α-synuclein on mitochondrial dynamics not only uncovers a common function of these key PARK genes in the mitochondrial stress response independent of mitophagy but also provides a physiological context for the prevalence of α-synuclein pathology in PD.
**EXPERIMENTAL PROCEDURES**

*Cell culture and transfection* - WT, Mfn1 KO, Mfn2 KO and Ubc13 KO MEFs were maintained in DMEM supplemented with 10% FCS and Pen/Strep (Gibco). HeLa cells were maintained in DMEM supplemented with 10% FBS and Pen/Strep. The YFP-Parkin permanent HeLa cells and the Flp-In parental HeLa cells were maintained in DMEM supplemented with 10% FBS, Pen/Strep and selection antibiotics, hygromycin and Zeocin (Invitrogen), respectively. All cell lines were cultured at 37°C and 5% CO2.

Neuron-enriched cultures were generated from cortex of male and female E16.5 CD1 mouse embryos (Charles River Laboratories). Briefly, the cortex was dissected, cells were dissociated with papain (Worthington Biochemicals), and the cell suspension was plated on poly-D-lysine/ Laminin-coated glass coverslips in Neurobasal medium with B27 supplements (Invitrogen) and Pen/Strep. Cultures were co-transfected with Parkin-shRNA plasmid and pcDNA3-EGFP using lipofectamine 2000 (Life Technologies) on day in vitro 3 (DIV3). At DIV6, the cells were treated with Rotenone, CCCP or DMSO control for 18 h prior to immunostaining.

**Antibodies, constructs and reagents** - Primary antibodies used in immunofluorescence were as follows: myc (9E10, mouse monoclonal), cytochrome c (mouse monoclonal; BD Biosciences), Tom20 (rabbit polyclonal; Santa Cruz), HA (HA.11, Covance) and FLAG (M2, Sigma Aldrich). Secondary antibodies used were as follows: Alexa-Fluor-594 donkey anti-mouse and anti-rabbit IgG (Molecular Probes), goat anti-rabbit Cy5 (Molecular Probes) and Pacific Blue goat anti-mouse IgG (Molecular Probes). Primary antibodies used in immunoblotting were: GFP (Roche), ubiquitin (total; P4D1, Santa Cruz), ubiquitin (K63-specific; Apu3, Millipore), α-synuclein (C20, Santa Cruz; 2462, Cell Signaling), Tim23 (BD Bioscience), GAPDH (Cell Signaling), synphilin (gift from S. Engleender) and parkin (Santa Cruz). HRP-conjugated secondary antibodies were used for immunoblotting (Promega).

The following plasmids were used: GFP-Parkin and mutants, as previously described (14); myc-Ubc13 (human, obtained from Kah-Leong Lim); HA-tagged Ub and mutant Ub constructs (obtained from Colin S. Duckett). Plasmids encoding shRNA against mouse Parkin (SHCLNV-NM_016694, Sigma-Aldrich) and human Pink1 (TRCN0000199193, Board Institute).

**Determination of CCCP concentrations** - As each cell type responds differently to CCCP, we tested a range of doses in each cell line used to determine which dose was appropriate for use in this study. We expressed GFP-Parkin (or in the case of the M17 cells, we compared control and parkin KD) and stained for mitochondria using cytochrome c antibodies. We analysed the mitochondria in control versus parkin-expressing cells to see at which concentration(s) there was a difference in morphology. We also checked for parkin translocation or mitochondrial aggregation/clearance, to confirm “mitophagy-inducing” concentrations of CCCP for each cell line.

**Analysis of mitochondrial morphology** - Mitochondrial morphology was quantified, as previously described (17). For each experiment, cells were divided into three categories: “hyperfused”, where the majority of mitochondria were so interconnected that individual mitochondria were rarely distinguishable, “intermediate”, where mitochondria were interconnected and tubular, but individual mitochondrial units were often distinguishable, and “fragmented”, where mitochondria were mostly short tubules or small, rounded units. 50 cells per condition were quantified in each sample of independent experiments. The average percentage of cells with each type of mitochondrial morphology was plotted + s.d. or +s.e.m. as indicated, and p-values were determined using the student’s t-test.

Fluorescence recovery after photobleaching (FRAP) was performed, as previously described (17). Briefly, cells were transfected with YFP targeted to the mitochondrial matrix (mito-YFP) and either control vector or Parkin (FLAG-tagged) with or without treatment. The data from each experiment can be shown in two forms: recovery, as plotted in line graph form, or mobile fraction. In the recovery curves, greater increases in normalised fluorescence intensity (y-axis) over
time in seconds (x-axis) represent more interconnected mitochondria. The mobile fraction of the mito-YFP was plotted in bar graphs, with larger mobile fractions representing more interconnected mitochondria. We utilised the mobile fraction graphing method for all of the FRAP experiments, and only showed the line graph in the first instance, Fig 1C. In each FRAP experiment, 15-20 cells were analysed per condition per cell type. The average was plotted + the s.e.m. FRAP experiments were performed in duplicate.

In addition to FRAP, we performed quantitative analysis of the mitochondrial network using image analysis in Metamorph. Images were acquired using standardized settings on the confocal microscope, with the laser intensity and brightness (gain) maintained at the same level for all images. Mitochondria were immunostained using cytochrome c antibody. Images were acquired at 63x, and 15-20 cells were analysed per condition. To obtain the network score, Metamorph software was used to measure the mitochondrial area as well as identify the number of resolvable structures (or individual mitochondrial units). The area was divided by the number of resolvable structures, which gave us a network score (or a quantitative measure of how interconnected the mitochondria were). A higher score represented a more fused mitochondrial network. The average network score was plotted for each cell type under the conditions, as listed, + S.D.

**Gene silencing and analysis** - For the α-synuclein knockdown, HeLa cells were transfected with a non-targeting, negative siRNA control (Invitrogen) or siRNA targeting human α-synuclein (Hs SCNA 1; Qiagen) using RNAiMAX (Invitrogen). After 96 hours, the cells were treated with 1 μM CCCP for an additional 18 hours. Then, the coverslips of control and α-synuclein KD cells were fixed and immunostained with cytochrome c. The whole cell lysates were also collected for analysis of KD efficiency by immunoblotting. To knockdown Parkin in primary neuronal cells, cortical neurons were co-transfected with plasmids encoding Parkin-shRNA and pcDNA-EGFP for 72 hours prior to further treatment.

**Immunoprecipitation** - HeLa cells were transfected with plasmids encoding GFP-tagged Parkin (wild type or A240R mutant). 36 hours after transfection, cells were treated with CCCP for 18 hours. DMSO was used as negative control. Cells were lysed in denaturing buffer (50 mM Tris-HCl, pH7.4, 0.5 mM EDTA and 1% SDS). Following a brief centrifugation, the lysates were diluted 10-fold in NETN buffer (50mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5% NP-40, 0.5 mM EDTA) supplied with the deubiquitinase inhibitor, NEM, and a protease inhibitor cocktail (Roche). The diluted lysates were subjected to overnight immunoprecipitation using the α-synuclein antibody (C20, Santa Cruz). After extensive washing, the immunoprecipitates were subjected to immunoblot analysis.

**Immunofluorescence** - Cells were cultured on glass cover slips (VWR) in 6-well dishes for one day prior to transfection. Treatment with DMSO control, CCCP or rotenone was performed the following day. Cells were fixed after treatment with 4% paraformaldehyde for 15 minutes at room temperature (RT). After one wash in 1x phosphate buffered saline (PBS), cells were permeabilised for 15 min (RT) in 0.15% TritonX100 (diluted in 1x PBS). Next, cells were blocked in 10% bovine serum albumin (BSA) for 20 minutes at RT. Cells were incubated in primary antibody solution overnight. Primary antibodies were diluted in 10% BSA. Following primary antibody incubation, cells were washed three times in 1x PBS, then incubated in secondary antibody solution, which was also made with 10% BSA. The incubation in secondary antibody solution was followed by three washes in 1x PBS. Finally, the samples were mounted onto glass slides (VWR) using Fluoromount-G mounting solution (SouthernBiotech) for imaging.

**Confocal image acquisition and analysis** - All images were acquired on a spinning-disk confocal microscope (Leica) using a 100x/1.40-0.70NA oil (Leica Plan Apochromat) objective. Images of fixed cells were acquired at room temperature and processed using the Leica LAS AF program software. FRAP analysis was performed at 37°C. Images contrast and brightness were adjusted in
Photoshop (Adobe). Quantitative recovery data from the FRAP analysis was analysed in Excel (Microsoft).

**Statistical analysis** - Two-way ANOVA analysis with Tukey’s test was conducted for statistical analysis of all quantitative data. Standard deviation or standard error was used, as labelled.

**RESULTS**

**Parkin promotes mitochondrial connectivity in response to moderate mitochondrial and oxidative stress**

In parkin-expressing cells, treatment with high concentration of the chemical uncoupler, carbonyl cyanide m-chlorophenylhydrazone (CCCP, 10-25 µM), causes parkin translocation to depolarized mitochondria, which are subsequently removed by mitophagy (9,14,18). As expected, when lower concentrations of CCCP were applied (100 nM-1 µM, see Materials and Methods), no apparent translocation of parkin to mitochondria or mitophagy was observed (Fig. 1A). Surprisingly, however, mitochondria in MEFs transiently expressing GFP-Parkin underwent marked elongation and networking, resulting in a “hyperfused” phenotype (Fig. 1A, arrows; Fig. 1B). This is in stark contrast to mitochondria in parkin-negative MEFs, which underwent fission and displayed a “fragmented” mitochondrial phenotype upon CCCP treatment (Fig. 1A, arrowheads; Fig. 1B), as it was previously reported (19). To confirm the morphological phenotype, we devised a mitochondrial “network score”, which was calculated as mitochondrial area divided by the number of individual mitochondria (Fig. 1C). Indeed, the network score was decreased in parkin-negative MEFs but increased in parkin-positive MEFs upon treatment with low dose CCCP (Fig. 1C).

To further quantify the connectivity of the mitochondrial network, we measured fluorescence recovery after photobleaching (FRAP) of a mitochondria-targeted YFP (mito-YFP), where connected mitochondria recover fluorescence more rapidly than isolated and fragmented ones. As shown in Fig. 1E-F, in cells lacking parkin, CCCP treatment caused a significant decrease in fluorescence recovery of mito-YFP (lower mobile fraction) compared to untreated cells, indicative of more fragmented mitochondria. In contrast, CCCP treatment accelerated the fluorescence recovery and significantly increased the mobile fraction in cells expressing parkin (Fig. 1D, purple line and 1E).

We next asked if parkin-dependent mitochondrial fusion could be activated by mitochondrial toxins and oxidative stresses that are linked to PD. As shown in Fig 1F-H, treatment with a low concentration of complex I inhibitor, rotenone (50 nM), also induced mitochondrial fusion in parkin-expressing cells but triggered mitochondrial fragmentation in parkin-negative HeLa cells. Similarly, hydrogen peroxide treatment, which produces reactive oxygen species (ROS), induced parkin-dependent mitochondrial fusion as well (Fig. 1I). Altogether, these results show that ectopically expressed parkin promotes mitochondrial connectivity in response to moderate mitochondrial stress.

**Endogenous parkin mediates mitochondrial hyperfusion in neuronal cells**

We next investigated whether endogenous parkin could induce mitochondrial fusion in response to mitochondrial and oxidative stressors in primary cortical neurons. As shown in Fig 2A-B, treatment with low-dose CCCP (20 nM) and rotenone (2 nM) also resulted in mitochondrial elongation in primary neurons. In contrast, the same treatment led to fragmented mitochondria when parkin was knocked down (Fig 2C-D).

Similar parkin-dependent mitochondrial fusion was observed in neuronal M17 cell line treated with CCCP, rotenone and hydrogen peroxide (Fig 2E). Taken together with the data in Figure 1, these findings show that both ectopic and endogenous parkin promote mitochondrial connectivity in response to moderate mitochondrial stress.

**Parkin-mediated mitochondrial fusion requires mitofusins**

Mitochondrial fusion is positively regulated by the mitofusins, Mfn1 and Mfn2 (20-22). To determine whether the parkin-induced hyperfused mitochondrial network requires the
mitochondrial fusion machinery, we examined the effect of parkin on mitochondrial connectivity in Mfn2 knockout (KO) MEFs, which show a fusion deficiency under basal conditions but can undergo fusion when challenged by nutrient starvation (23). As shown in Fig. 3A-B, expression of GFP-Parkin in Mfn2 knockout (KO) MEFs did not induce a hyperfused mitochondrial phenotype upon CCCP treatment, a conclusion confirmed by the FRAP-based mitochondrial connectivity assay (Fig. 3C). Similar data were found in Mfn1 KO cells (data not shown). Thus, the mitochondrial fusion machinery is required for the formation of the hyper-connected mitochondrial network induced by parkin and mitochondrial stress.

**Parkin-mediated mitochondrial fusion requires PINK1**

Genetic evidence has indicated that PINK1 and parkin work in the same pathway to maintain mitochondrial integrity (4,5). To determine if PINK1 is also involved in parkin-mediated mitochondrial morphological remodelling, we inactivated PINK1 by a specific siRNA and assessed CCCP-induced mitochondrial fusion in HeLa cells stably expressing YFP-tagged parkin. As shown in Figure 4, PINK1 knockdown effectively suppressed parkin-dependent mitochondrial fusion upon treatment with low doses of CCCP. These data indicate that the PINK1-parkin mitochondrial quality control axis also operates to stimulate mitochondrial fusion in response to mitochondrial stress.

**Parkin-mediated mitochondrial fusion requires its ubiquitin E3 ligase activity**

Parkin encodes for an ubiquitin E3-ligase. To investigate whether stress-induced mitochondrial fusion requires parkin-mediated ubiquitination, we assessed the PD-associated parkin mutants that are deficient in E3-ligase activity, A240R and T415N. We found that these mutants cannot promote a hyperfused mitochondrial phenotype upon rotenone (Fig. 5A-B) or CCCP treatment (data not shown). These results indicate that parkin-mediated ubiquitination is required for stimulating mitochondrial fusion in response to mitochondrial stress.

**Parkin-dependent mitochondrial fusion requires K63-linked ubiquitination**

Our results with the A240R and T415N parkin mutants indicate that the ubiquitin E3-ligase activity of parkin is required for stress-induced mitochondrial fusion. Parkin has been shown to catalyze both K48-linked and K63-linked ubiquitin chains during mitophagy (13,24). To determine which type of ubiquitin chain is responsible for mitochondrial fusion, we overexpressed mutant ubiquitin, K48R or K63R, to suppress K48- and K63-linked ubiquitin chain production, respectively. As shown in Fig 6A-B, the expression of a K63R, but not a K48R, ubiquitin mutant significantly inhibited CCCP-induced, parkin-dependent mitochondrial fusion. Supporting this observation, inactivation of Ubc13, an ubiquitin-conjugating enzyme that assembles K63 ubiquitin chains with parkin (25), prevented parkin-dependent mitochondrial fusion in response to CCCP (Fig. 6C-D) or rotenone treatment (data not shown). Mitochondrial fusion in Ubc13-deficient cells was restored by re-introduction of an Ubc13 expression plasmid (Fig. 6C-D). Taken together, these data indicate that parkin-mediated mitochondrial fusion requires Ubc13-mediated K63-linked ubiquitination.

**Parkin promotes ubiquitination-dependent α-synuclein and synphilin 1 complex formation in response to mitochondrial stress**

Overexpression of α-synuclein (PARK1) has been shown to induce mitochondrial fission (26,27). We therefore asked if α-synuclein is a regulatory target of parkin in response to mitochondrial stress. Co-immunoprecipitation assays showed that α-synuclein and parkin did not form stable complexes under basal conditions (Fig. 7A (i), Lane 1), as it was previously reported (28). However, upon CCCP treatment, endogenous α-synuclein became markedly associated with parkin (Fig. 7A (i), Lane 2). Remarkably, the formation of the parkin-α-synuclein complex is accompanied by the prominent appearance of ubiquitinated species (Fig. 7A (ii), Lane 2, bracket). In contrast, the ubiquitin-ligase deficient A240R parkin mutant, which cannot support mitochondrial fusion (Fig 5), did not stably associate with α-synuclein (Fig. 7A (i), Lane 4) or induce ubiquitinated species (Fig. 7A (ii), Lane 4) in response to CCCP. Low-dose rotenone treatment similarly induced parkin-α-synuclein association.
and ubiquitination (Fig 7B, Lane 3). Consistent with the finding that parkin stimulates mitochondrial fusion by catalyzing Ubc13-dependent K63-linked ubiquitin chain formation (Fig. 6), the parkin-mediated ubiquitinated species were recognized by a K63-linked ubiquitin chain-specific antibody (Fig. 7A (iii), Lane 2, bracket). Furthermore, knockdown of Ubc13 markedly reduced α-synuclein-associated ubiquitination upon treatment with CCCP or rotenone (Fig 7B, Lane 5-6).

We found that CCCP and rotenone treatments also recruited synphilin 1, a negative regulator of α-synuclein toxicity (28-30), to the α-synuclein-parkin complex (Fig 7B, Lane 2-3). Importantly, knockdown of Ubc13 not only reduced α-synuclein-associated ubiquitination but also synphilin 1 recruitment, indicating that parkin-mediated K63-linked ubiquitination promotes an interaction of α-synuclein and synphilin 1 (Fig 7B). These findings show that in response to mitochondrial stress, parkin becomes physically associated with α-synuclein, catalyzes ubiquitination, and recruits synphilin 1.

**α-synuclein is required for stress-induced mitochondrial fission**

The parkin-dependent recruitment of synphilin 1 suggests that parkin negatively regulates α-synuclein in response to mitochondrial stress. To directly assess the role of α-synuclein in stress-induced mitochondrial remodelling, we knocked down α-synuclein by siRNA in parkin-negative HeLa cells followed by modest levels of CCCP treatment. As shown in Fig. 8A-C, inactivation of α-synuclein, similar to parkin expression, effectively suppressed mitochondrial fission normally induced by CCCP. These results support the notion that parkin negatively regulates α-synuclein in response to mitochondrial stress.

**DISCUSSION**

The loss of mitochondrial integrity and appearance of Lewy bodies are two prevailing pathological features of Parkinson's disease (PD). Parkin has been proposed to play a key role in maintaining mitochondrial QC by disposing of damaged mitochondria through mitophagy. We have discovered that under moderate mitochondrial stress conditions, parkin promotes mitochondrial connectivity instead of parkin translocation and mitophagy. Several lines of evidence support the physiological relevance of parkin-mediated mitochondrial fusion. First, parkin activates mitochondrial fusion in response to mitochondrial stresses known to associate with PD pathogenesis. Second, several PD-causing parkin mutants are defective in stimulating mitochondrial fusion. Lastly, parkin-dependent fusion of stressed mitochondria requires PINK1 and involves parkin-α-synuclein interaction and ubiquitination. These findings connect three key PARK genes to mitochondrial morphological remodelling in response to mitochondrial stresses.

Although low levels of CCCP do not fully collapse the mitochondrial membrane potential and activate parkin-mediated mitophagy, this treatment likely elevates mitochondrial stress by stimulating oxidative phosphorylation to maintain the mitochondrial proton gradient. Modest levels of rotenone and H2O2 could similarly increase mitochondrial oxidative stress. Under these modest mitochondrial stress conditions, parkin-negative cells did not show acute mitochondrial failure (<24 hr treatment), judging by ATP production, or increased cell death (data not shown). These findings are in line with a rat PD model where low levels of rotenone did not induce acute bioenergetic defects but chronic treatment resulted in PD-like phenotypes, including the appearance of Lewy body-like inclusions (8). Our evidence indicates that parkin-mediated mitochondrial fusion is an adaptive response to mitochondrial stress. Consistent with our findings, mitochondria in parkin-mutant fibroblasts from AR-JP patients are also much more prone to fragmentation than those in control cells when challenged by low-dose rotenone (31). We propose that adaptive mitochondrial fusion mediated by parkin confers protection to mitochondria against low but chronic mitochondrial stress, which is likely more physiologically relevant to PD pathogenesis than high dose mitochondrial toxins commonly used to induce acute neuron dysfunction and death. Consistent with this proposition, mitochondria in parkin-mutant fibroblasts from AR-JP patients are...
more prone to fragmentation than those in control cells when challenged by low-dose rotenone (31).

In principle, active fusion could protect mitochondrial integrity by complementing damaged mitochondria with their healthy counterparts (32) or by limiting the production of reactive oxygen species (ROS) (33). Supporting this view, prominent accumulation of damaged mitochondria and neurodegeneration have been observed in fusion-deficient Mfn1/Mfn2 knockout cells and mice (34-36). We suggest that PINK1 and parkin form a sensor-effector pair that monitors internal mitochondrial status and enforces mitochondrial quality control accordingly. In response to mitochondrial stresses, cytosolic parkin, in conjunction with PINK1, initially promotes the formation of a connected mitochondrial network to protect mitochondria from further damage. Irreparably damaged mitochondria are subsequently targeted by parkin and PINK1 to undergo destruction by mitophagy. The step-wise ubiquitin-dependent triage system could offer more efficient and better management of mitochondrial QC.

Our study has identified α-synuclein (PARK1) as a regulatory target of parkin in the mitochondrial stress response. Despite the extensive characterization of α-synuclein in PD, its physiological function remains elusive. We found that inactivation of α-synuclein by siRNA essentially phenocopies the effect of parkin and suppresses stress-induced mitochondrial fission (Fig. 8). This finding indicates that α-synuclein normally promotes mitochondrial fragmentation in response to mitochondrial stress. We suspect that α-synuclein-mediated mitochondrial fission is part of an adaptive response to mitochondrial stress. Indeed, although α-synuclein has been predominantly considered a PD-causing gene, genetic ablation of α-synuclein in mice actually leads to aberrant mitochondrial lipid composition and function (37). Dopaminergic neurons from α-synuclein knockout mice are more susceptible to oxidative stress than their wild type counterparts (38,39). These findings suggest a physiological and protective role of α-synuclein in the mitochondrial stress response. However, prolonged or unchecked activation of α-synuclein caused by chronic mitochondrial stress or mutations in parkin or PINK1 would lead to excessive mitochondrial fission, mitochondrial failure, and eventually neuron cell death and PD. Indeed, over-expression of α-synuclein induces mitochondrial fragmentation and dysfunction along with neurodegeneration (26,27).

Our data suggest that parkin terminates the α-synuclein-mediated mitochondrial stress response by catalyzing Ubc13-dependent, K63-linked ubiquitination. We further found that this ubiquitination induces formation of a protein complex of parkin, α-synuclein and synphilin 1 (Fig 7). These findings are of potential significance for several reasons. First, synphilin 1 over-expression can suppress neurotoxicity caused by a PD-associated α-synuclein (A53T) mutant transgene (30). Thus, recruitment of synphilin 1 by parkin would inhibit α-synuclein. Second, in both cells and mice, synphilin 1 stimulates α-synuclein to form inclusion bodies that resemble Lewy bodies (28-30,40). Lastly, we have previously shown that K63-linked ubiquitin chains are critical for both biogenesis and clearance of the aggresome, a cellular model for Lewy bodies (41,42). These findings lead us to propose that parkin terminates stress-activated α-synuclein by catalyzing K63-linked ubiquitination and recruiting synphilin 1, which could activate transport and autophagic degradation of α-synuclein-synphilin 1 complexes induced by parkin in an attempt to resolve chronic mitochondrial stress. Accordingly, for AR-JP patients deficient in parkin, the inability to terminate α-synuclein activity through K63-linked ubiquitination results in premature mitochondrial failure and early onset neurodegeneration in the absence of Lewy bodies (43).

The convergence of α-synuclein, parkin and PINK1 on mitochondrial dynamics, along with the contribution of DJ-1 (26,31,44), underscores the significance of adaptive mitochondrial fusion in maintaining mitochondrial integrity when challenged by stress conditions relevant to PD. The interplay of parkin, α-synuclein, and synphilin 1 in response to mitochondrial toxins further provides a
physiological basis for the prevalence of Lewy bodies in PD. It is of interest to note that no ortholog of α-synuclein has been found in Drosophila. Therefore, the observed relationship between parkin and α-synuclein must have evolved later in evolution, possibly reflecting the need to better manage mitochondrial stresses and protect neurons in animals with much longer lifespans than fruit flies. In the future, elucidating the specific functions of α-synuclein would be crucial to understand how mitochondria adapt to endogenous and exogenous stresses and the physiological basis of neurodegenerative diseases characterized by α-synuclein pathology.
references

1. Abou-Sleiman, P. M., Muqit, M. M., and Wood, N. W. (2006) Nat Rev Neurosci 7, 207-219
2. Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., and Pallanck, L. J. (2003) Proceedings of the National Academy of Sciences of the United States of America 100, 4078-4083
3. Whitworth, A. J., Theodore, D. A., Greene, J. C., Benes, H., Wes, P. D., and Pallanck, L. J. (2005) Proceedings of the National Academy of Sciences of the United States of America 102, 8024-8029
4. Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., and Guo, M. (2006) Nature 441, 1162-1166
5. Park, M., Salgado, J. M., Ostroff, L., Helton, T. D., Robinson, C. G., Harris, K. M., and Ehlers, M. D. (2006) Neuron 52, 817-830
6. Yang, B., Zhao, D., and Verkman, A. S. (2006) The Journal of biological chemistry 281, 16202-16206
7. Dexter, D. T., Sian, J., Rose, S., Hindmarsh, J. G., Mann, V. M., Cooper, J. M., Wells, F. R., Daniel, S. E., Lees, A. J., Schapira, A. H., and et al. (1994) Annals of neurology 35, 38-44
8. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000) Nat Neurosci 3, 1301-1306
9. Narendra, D., Tanaka, A., Suen, D. F., and Youle, R. J. (2008) The Journal of cell biology 183, 795-803
10. Geisler, S., Holmstrom, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., and Springer, W. (2010) Nature cell biology 12, 119-131
11. Matsuda, N., Sato, S., Shibahara, K., Okatsu, K., Saisho, K., Gutiérrez, C. A., Sou, Y. S., Saiki, S., Kawajiri, S., Sato, F., Kimura, M., Komatsu, M., Hattori, N., and Tanaka, K. (2010) The Journal of cell biology 189, 211-221
12. Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L., Kim, J., May, J., Tocilescu, M. A., Liu, W., Ko, H. S., Magrane, J., Moore, D. J., Dawson, V. L., Grailhe, R., Dawson, T. M., Li, C., Tieu, K., and Przedborski, S. (2010) Proceedings of the National Academy of Sciences of the United States of America 107, 378-383
13. Chan, N. C., Salazar, A. M., Pham, A. H., Sweredoski, M. J., Kolawa, N. J., Graham, R. L., Hess, S., and Chan, D. C. (2011) Human molecular genetics
14. Lee, J. Y., Nagano, Y., Taylor, J. P., Lim, K. L., and Yao, T. P. (2010) The Journal of cell biology 189, 671-679
15. Yoshii, S. R., Kishi, C., Ishihara, N., and Mizushima, N. (2011) The Journal of biological chemistry 286, 19630-19640
16. Narendra, D., Kane, L. A., Hauser, D. N., Fearnley, I. M., and Youle, R. J. (2010) Autophagy 6, 1090-1106
17. Karbowski, M., Norris, K. L., Cleland, M. M., Jeong, S. Y., and Youle, R. J. (2006) Nature 443, 658-662
18. Tanaka, A., Cleland, M. M., Xu, S., Narendra, D. P., Suen, D. F., Karbowski, M., and Youle, R. J. (2010) The Journal of cell biology 191, 1367-1380
19. Legros, F., Lombes, A., Frachon, P., and Rojo, M. (2002) Molecular biology of the cell 13, 4343-4354
20. Chen, H., Detmer, S. A., Ewald, A. J., Griffin, E. E., Fraser, S. E., and Chan, D. C. (2003) The Journal of cell biology 160, 189-200
Parkin stimulates adaptive mitochondrial fusion

21. Rapaport, D., Brunner, M., Neupert, W., and Westermann, B. (1998) *The Journal of biological chemistry* **273**, 20150-20155
22. Hermann, G. J., Thatcher, J. W., Mills, J. P., Hales, K. G., Fuller, M. T., Nunnari, J., and Shaw, J. M. (1998) *The Journal of cell biology* **143**, 359-373
23. Rambold, A. S., Kostelecky, B., Elia, N., and Lippincott-Schwartz, J. (2011) *Proceedings of the National Academy of Sciences of the United States of America* **108**, 10190-10195
24. Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D. F., Gautier, C. A., Shen, J., Cookson, M. R., and Youle, R. J. (2010) *PLoS biology* **8**, e1000298
25. Doss-Pepe, E. W., Chen, L., and Madura, K. (2005) *The Journal of biological chemistry* **280**, 16619-16624
26. Kamp, F., Exner, N., Lutz, A. K., Wender, N., Hegermann, J., Brunner, B., Nuscher, B., Bartels, T., Giese, A., Beyer, K., Eimer, S., Winkelhofer, K. F., and Haass, C. (2010) *The EMBO journal* **29**, 3571-3589
27. Nakamura, K., Nemani, V. M., Azarbal, F., Skibinski, G., Levy, J. M., Egami, K., Mushkina, L., Zhang, J., Gardner, B., Wakabayashi, J., Sesaki, H., Cheng, Y., Finkbeiner, S., Nussbaum, R. L., Maslia, E., and Edwards, R. H. (2011) *The Journal of biological chemistry* **286**, 20710-20726
28. Chung, K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2001) *Nature medicine* **7**, 1144-1150
29. Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., Margolis, R. L., Troncoso, J. C., Lanahan, A. A., Worley, P. F., Dawson, V. L., Dawson, T. M., and Ross, C. A. (1999) *Nature genetics* **22**, 110-114
30. Smith, W. W., Liu, Z., Liang, Y., Masuda, N., Swing, D. A., Jenkins, N. A., Copeland, N. G., Troncoso, J. C., Pletnikov, M., Dawson, T. M., Martin, L. J., Moran, T. H., Lee, M. K., Borchelt, D. R., and Ross, C. A. (2010) *Human molecular genetics* **19**, 2087-2098
31. Mortiboys, H., Thomas, K. J., Koopman, W. J., Klaflke, S., Abou-Sleiman, P., Olpin, S., Wood, N. W., Willems, P. H., Smeitink, J. A., Cookson, M. R., and Bandmann, O. (2008) *Annals of neurology* **64**, 555-565
32. Nakada, K., Sato, A., and Hayashi, J. (2009) *The international journal of biochemistry & cell biology* **41**, 1907-1913
33. Lee, J. Y., Kapur, M., Li, M., Choi, M. C., Choi, S., Kim, H. J., Kim, I., Lee, E., Taylor, J. P., and Yao, T. P. (2014) *Journal of cell science* **127**, 4954-4963
34. Chen, S., Owens, G. C., Makarenkova, H., and Edelman, D. B. (2010) *PloS one* **5**, e10848
35. Chen, H., Vermulst, M., Wang, Y. E., Chomyn, A., Prolla, T. A., McCaffery, J. M., and Chan, D. C. (2007) *Cell* **131**, 280-289
36. Pham, A. H., Meng, S., Chu, Q. N., and Chan, D. C. (2012) *Human molecular genetics* **21**, 4817-4826
37. Ellis, C. E., Murphy, E. J., Mitchell, D. C., Golovko, M. Y., Scaglia, F., Barcelo-Coblijn, G. C., and Nussbaum, R. L. (2005) *Molecular and cellular biology* **25**, 10190-10201
38. Dauer, W., Kholodilov, N., Vila, M., Trillat, A. C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., Rocha, M., Jackson-Lewis, V., Hersch, S., Sulzer, D., Przedborski, S., Burke, R., and Hen, R. (2002) *Proceedings of the National Academy of Sciences of the United States of America* **99**, 14524-14529
39. Musgrove, R. E., King, A. E., and Dickson, T. C. (2013) *Neurotoxicity research* **23**, 358-369
Parkin stimulates adaptive mitochondrial fusion

40. Lim, K. L., Chew, K. C., Tan, J. M., Wang, C., Chung, K. K., Zhang, Y., Tanaka, Y., Smith, W., Engelender, S., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2005) *J Neurosci* **25**, 2002-2009

41. Tan, J. M., Wong, E. S., Kirkpatrick, D. S., Pletnikova, O., Ko, H. S., Tay, S. P., Ho, M. W., Troncoso, J., Gygi, S. P., Lee, M. K., Dawson, V. L., Dawson, T. M., and Lim, K. L. (2008) *Human molecular genetics* **17**, 431-439

42. Hao, R., Nanduri, P., Rao, Y., Panichelli, R. S., Ito, A., Yoshida, M., and Yao, T. P. (2013) *Molecular cell* **51**, 819-828

43. Miyakawa, S., Ogino, M., Funabe, S., Uchino, A., Shimo, Y., Hattori, N., Ichinoe, M., Mikami, T., Saegusa, M., Nishiyama, K., Mori, H., Mizuno, Y., Murayama, S., and Mochizuki, H. (2013) *Movement disorders : official journal of the Movement Disorder Society* **28**, 388-391

44. Irrcher, I., Aleyasin, H., Seifert, E. L., Hewitt, S. J., Chhabra, S., Phillips, M., Lutz, A. K., Rousseaux, M. W., Bevilaqua, L., Jahani-Asl, A., Callaghan, S., Maclaurin, J. G., Winklhofer, K. F., Rizzu, P., Rippstein, P., Kim, R. H., Chen, C. X., Fon, E. A., Slack, R. S., Harper, M. E., McBride, H. M., Mak, T. W., and Park, D. S. (2010) *Human molecular genetics* **19**, 3734-3746

45. Kim, K. Y., Stevens, M. V., Akter, M. H., Rusk, S. E., Huang, R. J., Cohen, A., Noguchi, A., Springer, D., Bocharov, A. V., Eggerman, T. L., Suen, D. F., Youle, R. J., Amar, M., Remaley, A. T., and Sack, M. N. (2011) *The Journal of clinical investigation* **121**, 3701-3712
Parkin stimulates adaptive mitochondrial fusion

Acknowledgements - We thank Dr. J. Chen for Ubc13 KO MEFs, Dr. D. C. Chan for the Mfn1 and Mfn2 KO MEFs. The Flp and YFP-Parkin HeLa cell lines were a generous gift from Dr. R. Youle. We also thank Dr. A. McClure for her thoughtful comments on the manuscript.

FOOTNOTES

* This work was supported by the National Institutes of Health [grant numbers T32-CA-059365 to K.L.N., 1R01DA033610 to A.E.W, 2R01-NS054022 to T.P.Y.]; and the Leukemia and Lymphoma Society [5396-11 to K.L.N].
1 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA, 27710
2 Department of Neurobiology, Duke University Medical Center, Durham, NC, USA, 27710
3 Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA, 38105
4 Department of Pharmacology, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 31096, Israel
5 Department of Physiology, National University of Singapore, Singapore
6 These authors contributed equally
7 To whom correspondence should be addressed: Tso-Pang Yao, Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710 Tel.: (919) 6138654; Fax: (919) 668-3954; E-mail: tsopang.yao@dm.duke.edu
The Abbreviations used are: CCCP, carbonyl cyanide m-chlorophenylhydrazone; MEF, mouse embryonic fibroblast; FRAP, fluorescence recovery after photobleaching; Mfn, mitofusin; PD, Parkinson's disease

Conflict of Interest statement. None declared.

FIGURE LEGENDS

FIGURE 1. Mitochondrial morphology in response to CCCP treatment.
A. Control (top) or 1 µM CCCP-treated (bottom) WT MEFs were transiently transfected with GFP-Parkin (green), and mitochondria were immunostained using cytochrome c (red) antibody. Scale bar represents 25 µm. Small squares represent 4x zoom images of cytochrome c staining (red only). Arrows (green) mark transfected cells and arrowheads (white) are cells not expressing GFP-Parkin (untransfected). B. Mitochondrial morphology was assessed in WT MEFs, and the percentage of cells (average ± S.D.) with hyperfused (blue bars), intermediate (red bars) or fragmented (green bars) was plotted. Cells were either control (-) or treated (+) with 1 µM CCCP for 18 hrs, as indicated. C. Mitochondrial morphology was analyzed quantitatively using image analysis and Metamorph software to derive the “network score”, or the ratio of mitochondrial area to number of individual mitochondria (“resolvable units”). For a more complete description, see the Materials and Methods. The network score was measured for WT MEFs expressing GFP-Parkin (versus control cells) with (red bars) or without (blue bars) treatment with CCCP (1 µM, 18 hrs). The average score ± S.D. is plotted. D. Connectivity of mitochondria in WT MEFs was quantitatively assessed using fluorescence recovery after photobleaching (FRAP). Cells were transfected with YFP targeted to the mitochondrial matrix (mito-YFP) and either control vector or parkin (FLAG-tagged) with or without treatment with 1 µM CCCP. Mito-YFP recovery is plotted, with greater increases in normalized fluorescence intensity (y-axis) over time in seconds (x-axis) representing more interconnected mitochondria. Data represent mean ± s.e.m. (n~20 cells per condition). E. The average mobile fraction (+ s.e.m.) of the mito-YFP from the FRAP experiment in Fig. 1C is plotted, with larger
Parkin stimulates adaptive mitochondrial fusion

mobile fractions representing more interconnected mitochondria. F. HeLa cells were transiently transfection with GFP-Parkin (green) and imaged as in Fig. 1A. Boxes 1 and 4 are transfected cells, 2 and 3 are untransfected cells. G. Mitochondrial morphology was assessed in HeLa cells treated with DMSO control or 50 μM rotenone for 2 hrs, and the data were plotted as in Fig. 1B. H. FRAP was performed in HeLa cells treated with rotenone (100 nM, 2 hrs) or control (DMSO), and the average mobile fraction was plotted as in Fig. 1D. I. HeLa cells transiently transfected with GFP-Parkin were treated with control or H$_2$O$_2$ (100 nM, 2 hrs), and mitochondrial morphology was assessed as in Fig. 1B. All statistical significance was assessed using two-way ANOVA analysis with Tukey’s test.

FIGURE 2. Parkin-dependent mitochondrial fusion in primary cortical neurons.
A. Mitochondria were immunostained using Tom20 antibody (red) in primary cortical neurons treated with DMSO, CCCP (20 nM), or rotenone (2 nM) for 18 hrs. Scale bar represents 10 μm. Right panels show zoomed areas (white squares). B. Mitochondrial morphology was assessed in primary neurons and data was plotted as in Fig. 1B. C. Primary cortical neurons were co-transfected with plasmids encoding Parkin-shRNA and pcDNA-EGFP. After 3 days, cells were treated with DMSO or Rotenone (2 nM) for an additional 18 h. Mitochondria were visualised using Tom20 antibody (red). Transfected cells were tracked with GFP signal (green). Right panels represent zoomed images of the white squares (Tom20 staining only). Cells expressing Parkin-shRNA are marked with green arrows; non-transfected cells are indicated with white arrowheads. D. Mitochondrial morphology was analysed in non-transfected and Parkin-shRNA expressing primary neurons. Cells were treated with DMSO or 2 nM rotenone for 18 hrs. Knockdown efficiency of the Parkin-shRNA has been confirmed previously (45). E. Mitochondrial morphology was analysed in cKD and parkin KD M17 cells treated with DMSO control, CCCP (100 nM), Rotenone (200 nM) or H$_2$O$_2$ (100 nM). All statistical significance was assessed using two-way ANOVA analysis with Tukey’s test.

FIGURE 3. Mitofusins are required for Parkin-mediated mitochondrial hyperfusion.
A. Control (top) and 1 μM CCCP-treated (bottom) Mfn2 KO MEFs were transiently transfected with GFP-Parkin (green) and imaged as in Fig. 1A. Arrows (green) mark transfected cells and arrowheads (white) are untransfected cells. B. Mitochondrial morphology was assessed in Mfn2 KO MEFs, and the data were plotted as in Fig. 1B. Cells were either control (-) or treated (+) with 1 μM CCCP for 18 hrs, as indicated. C. Connectivity of mitochondria in Mfn2 KO MEFs was quantitatively assessed using FRAP, as in Fig. 1D. All statistical significance was assessed using two-way ANOVA analysis with Tukey’s test but p-values were not significant in Mfn2 KO experiments (p>0.05).

FIGURE 4. PINK1 is required for parkin-mediated mitochondrial hyperfusion.
A. HeLa cells stably expressing YFP-parkin were co-transfected with plasmids encoding Pink1-shRNA and pcDNA-EGFP. Cells were treated with DMSO or CCCP (100 nM, 18 hrs). Transfected cells were tracked with exogenous EGFP signal (shown in green, cells indicated with green arrows in zoomed in panels) and mitochondria were immunostained using a Tom20 antibody. Scale bar represents 10 μm. B. Mitochondrial morphology was assessed in non-transfected and PINK1-shRNA expressing YFP-Parkin HeLa cells treated with DMSO or 100 nM CCCP for 18 hrs. The average + S.D. was plotted. All statistical significance was assessed using two-way ANOVA analysis with Tukey’s test.

FIGURE 5. Ubiquitination-deficient Parkin mutants fail to induce mitochondrial fusion.
A. Confocal microscope images of HeLa cells transiently transfected with GFP-tagged parkin mutants (A240R, top two rows; T415N, bottom two rows) and either left untreated or treated with 100 nM of rotenone for 2 hrs are shown. Mitochondria were visualised as in Fig. 1A. Scale bar represents 25 μm. Far right images are 5x zoom magnification of the white-boxed region of the overlay (cytochrome c staining only, red). B. Mitochondrial morphology was assessed as in Fig. 1B. HeLa cells expressing empty vector
Parkin stimulates adaptive mitochondrial fusion

Average values ± S.D. are shown. All p-values were assessed using two-way ANOVA analysis with Tukey’s test. C. Expression of GFP-tagged parkin was tested by immunoblotting with the indicated antibody. Tubulin served as internal control.

FIGURE 6. Parkin-mediated hyperfusion is K63 ubiquitin-dependent.

A. HeLa cells treated with CCCP (100 nM, 18 hrs) were transiently transfected with GFP-Parkin (green) and HA-tagged wild type, K63R or K48R mutant Ub (blue), as labelled. Mitochondria (mito) were immunostained using a Tom20 (red) antibody. The scale bar represents 25 μm. Small squares represent 3x zoom images (cytochrome c staining only, red). Transfected cells are marked with green arrows; untransfected cells are indicated with white arrowheads. B. Mitochondrial morphology was assessed in HeLa cells and plotted as in Fig. 1B. Cells were treated with DMSO (-) or 100 nM CCCP (+) for 18 hrs. The constructs used for transient transfection are marked. C. (Top two panels) Ubc13 KO MEFs were transiently transfected with GFP-Parkin (green) and mitochondria were immunostained as in Fig. 1A. The scale bar represents 25 μm. Small squares represent 4x zoom images (cytochrome c staining only, red). Control cells were treated with DMSO, whereas treated cells were incubated with 1 μM CCCP for 18 hrs, as indicated. (Bottom two panels) Ubc13 KO MEFs were transfected, stained and treated as in Fig. 5A, except Ubc13 expression was reconstituted using transient transfection of a myc-tagged Ubc13 construct, shown by anti-myc immunofluorescence (blue). Transfected cells are marked with green arrows; untransfected cells are indicated with white arrowheads. D. Mitochondrial morphology was assessed in Ubc13 KO MEFs, and data were plotted as in Fig. 1B. Cells were either control (-) or treated (+) with 1 μM CCCP, as indicated. All statistical significance was assessed using two-way ANOVA analysis with Tukey’s test.

FIGURE 7. Parkin binds α-synuclein under stress and results in α-synuclein-associated protein ubiquitination.

A. HeLa cells transiently expressing GFP-Parkin WT or A240R were treated with DMSO control (-) or 1 μM CCCP (+) for 18 hrs. Endogenous α-synuclein was immunoprecipitated (IP) and the samples were immunoblotted (IB), as indicated. Ubiquitinated species are marked by brackets. B. HeLa cells stably expressing YPF-parkin were transfected with either control or ubc13 siRNA. 48 hrs after transfection, cells were treated with DMSO control, CCCP (0.5 μM) or Rotenone (50 nM) for 18 hrs. Endogenous immunoprecipitation and whole cell lysate input were analysed by western blotting with anti-α-synuclein and other antibodies, as indicated.

FIGURE 8. α-synuclein is required for stress-induced mitochondrial fission

A. Confocal micrographs of control (cKD) and α-synuclein (syn) KD HeLa cells treated with DMSO or 1 μM CCCP for 18 hrs, as labelled, are shown. Mitochondria were imaged using cytochrome c antibodies (shown in green). Scale bar represents 25 μm. Small squares represent 5x zoom images. B. Mitochondrial morphology was assessed in control (cKD) and syn KD HeLa cells treated with DMSO (-) or 1 μM CCCP for 18 hrs (+). The average ± S.D. was plotted. The statistical significance was assessed using two-way ANOVA analysis with Tukey’s test. C. Western blot of whole cell lysates from control (cKD) and syn KD samples, treated with DMSO control (-) or 1 μM CCCP and immunoblotted with α-synuclein and tubulin, as labelled, are shown.
Figure 2- Norris, et al.

A. Cortical Neurons

B. Mitochondrial Morphology (% of cells)

C. Cortical Neurons

D. Mitochondrial Morphology (% of cells)

E. M17

- Hyperfused
- Intermediate
- Fragmented

DMSO
CCCP
Rotenone

Hyperfused
Intermediate
Fragmented

DMSO
Rotenone

Non-Transfected
Parkin-KD

pp<0.005

pp<0.0014

pp<0.034

pp<0.0014

pp<0.0002

pp<0.0031

pp<0.0461

pp<0.0332

pp<0.0146

pp<0.0332

pp<0.0461

pp<0.0031

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002

pp<0.0002
Parkin stimulates adaptive mitochondrial fusion

Figure 5 - Norris, et al.

A. Untreated and Rotenone-treated cells stained with GFP-A240R and GFP-T415N showing mitochondrial distribution.

B. Bar graph showing the percentage of hyperfused mitochondria in different conditions: Control, GFP-Parkin (WT), A240R, and T415N.

C. Western blot analysis showing the expression levels of GFP and Tubulin under different treatments.
Figure 7 - Norris, et al.

A. IP: endogenous α-synuclein

B. IP: endogenous α-synuclein

Input
Figure 8- Norris, et al.

A. [Images showing mitochondrial fusion under different conditions: cKD (DMSO), cKD (CCCP), α-syn KD (DMSO), α-syn KD (CCCP).]

B. [Bar chart showing mitochondrial morphology (% of cells) under different conditions: cKD and syn KD with and without CCCP.]

C. [Western blot images showing α-Synuclein and Tubulin levels under different conditions: CCCP and syn KD.]

Parkin stimulates adaptive mitochondrial fusion.
Convergence of parkin, PINK1 and α-synuclein on stress-induced mitochondrial morphological remodelling

Kristi L. Norris, Rui Hao, Liang-Fu Chen, Chun-Hsiang Lai, Meghan Kapur, Peter J. Shaughnessy, Dennis Chou, Jin Yan, J. Paul Taylor, Simone Engelender, Anna E. West, Kah-Leong Lim and Tso-Pang Yao

J. Biol. Chem. published online April 10, 2015

Access the most updated version of this article at doi: 10.1074/jbc.M114.634063

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts